Oryzon Genomics SA (ES:ORY)
BME:ORY
Holding ES:ORY?
Track your performance easily

Oryzon Genomics SA (ORY) Financial Statements

9 Followers

Oryzon Genomics SA Financial Overview

Oryzon Genomics SA's market cap is currently ―. The company's EPS TTM is €-0.064; its P/E ratio is -25.30; Oryzon Genomics SA is scheduled to report earnings on March 3, 2025, and the estimated EPS forecast is €-0.03. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Jun 21
Income Statement-
Total Revenue€ 0.00€ 0.00€ 0.00€ 0.00€ 0.00
Gross Profit----€ 1.73M
EBIT€ 9.99M€ -4.93M€ 1.81M€ -4.99M€ 1.47M
EBITDA€ 9.99M€ -4.93M€ 1.81M€ -4.99M€ 1.47M
Net Income Common Stockholders€ -2.32M€ -618.00K€ 325.08K€ -1.62M€ 801.13K
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments€ 21.32M€ 27.08M€ 22.72M€ 25.11M€ 33.73M
Total Assets€ 103.70M€ 103.16M€ 96.34M€ 92.70M€ 95.28M
Total Debt€ 17.44M€ 0.00€ 14.45M€ 0.00€ 11.37M
Net Debt€ -3.88M€ -27.08M€ -8.26M€ -25.11M€ -22.35M
Total Liabilities€ 31.13M€ 33.91M€ 26.22M€ 23.44M€ 20.35M
Stockholders Equity€ 72.57M€ 69.25M€ 70.12M€ 69.25M€ 74.93M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in EUR

Oryzon Genomics SA Earnings and Revenue History

Oryzon Genomics SA Debt to Assets

Oryzon Genomics SA Cash Flow

Oryzon Genomics SA Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis